# ENANTA PHARMACEUTICALS, INC (ENTA) · Edgar & Edgarette company card

> Enanta Pharmaceuticals (ENTA) saw revenue fall 3.4% in FY2025 to $65 million, operating margin -131% against a -3.8% median for pharmaceutical preparations, equity 23.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1177648 · fiscal year ended 2025-09-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/ENTA) · [JSON](https://www.pops4.com/boards/company/ENTA.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $65M |
| Revenue growth, 1 year | -3.4% |
| Revenue growth per year | -9.4% |
| Operating margin | -130.7% (prior year -179.9%) |
| Net margin | -125.4% |
| Operating cash flow | −$19M |
| Capital spending | $13M |
| Free cash flow | −$32M |
| Cash | $32M |
| Long-term debt | — |
| Total assets | $281M |
| Total equity | $65M |
| Equity ÷ assets | 23.1% |
| Return on equity | -126.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.79 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; revenue is hard to predict: its 80% range is ±36%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $65.3M (FY2025). Experience: revenue down 3.4% on the year, down 9.4% a year over 4 years; operating margin -130.7%, up from -179.9%. Soundness: equity 23.1% of assets, return on equity -126.5%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $40.6M and $86.7M next year (method v4.1: its own 6-year record of growth weighed at 63% against $50M–100M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $41.7M to $84.4M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -130.7% against a -3.8% median; growth -3.4% against 13.7%.

Range logged 2026-10-29, receipt 07d710eed975683e, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-10-28 ([filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526435092/0001193125-26-435092-index.htm))

## Recent filings

- 8-K · filed 2026-10-28 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526435092/0001193125-26-435092-index.htm)
- 10-Q · filed 2026-08-12 · [filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526345719/0001193125-26-345719-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/0001193125-26-342336-index.htm)
- 8-K · filed 2026-07-02 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526294837/0001193125-26-294837-index.htm)
- 8-K · filed 2026-06-23 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526279803/0001193125-26-279803-index.htm)
- 8-K · filed 2026-06-18 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1177648/000119312526274950/0001193125-26-274950-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001177648.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1177648

## Cite

POPS4, Edgar & Edgarette: ENANTA PHARMACEUTICALS, INC (ENTA) company card, from the company's own SEC filings, accessed 2026-10-29, https://www.pops4.com/boards/company/ENTA. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.